Literature DB >> 15131692

Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis.

V Savant, T Saeed, A Denniston, P I Murray.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131692     DOI: 10.1038/sj.eye.6700703

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  7 in total

Review 1.  Advances in the management of acute retinal necrosis.

Authors:  Jessica G Shantha; Heather M Weissman; Matthew R Debiec; Thomas A Albini; Steven Yeh
Journal:  Int Ophthalmol Clin       Date:  2015

2.  Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome (an American Ophthalmological Society thesis).

Authors:  Christina J Flaxel; Steven Yeh; Andreas K Lauer
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

3.  [Acute retinal necrosis from the virologist's perspective].

Authors:  P Rautenberg; L Grancicova; J Hillenkamp; B Nölle; J B Roider; H Fickenscher
Journal:  Ophthalmologe       Date:  2009-12       Impact factor: 1.059

4.  Antiviral selection in the management of acute retinal necrosis.

Authors:  Patrick M K Tam; Claire Y Hooper; Susan Lightman
Journal:  Clin Ophthalmol       Date:  2010-02-02

Review 5.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

6.  Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection.

Authors:  Victoria Wy Wong; Carmen Km Chan; Dexter Yl Leung; Timothy Yy Lai
Journal:  Clin Ophthalmol       Date:  2012-04-17

7.  Valacyclovir in the treatment of acute retinal necrosis.

Authors:  Simon Rj Taylor; Robin Hamilton; Claire Y Hooper; Lavnish Joshi; Jiten Morarji; Nitin Gupta; Sue L Lightman
Journal:  BMC Ophthalmol       Date:  2012-09-05       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.